SynthesisBMC infectious diseases2019
Accumulate evidence for IP-10 in diagnosing pulmonary tuberculosis.
Synthesis in BMC infectious diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Immune dysregulation in tuberculosis-diabetes comorbidity: mechanistic and translational insights.Frontiers in immunology · 2026Pooled it
- Monokine induced by gamma interferon for detecting pulmonary tuberculosis: A diagnostic meta-analysis.Medicine · 2020Pooled it
- Integrative Multi-Omics Reveals Serum Markers of Tuberculosis in Advanced HIV.Frontiers in immunology · 2021Trial
- Head-to-head evaluation of host blood biomarkers for point-of-care TB triage: diagnostic accuracy study.Journal of clinical microbiology · 2026Article
- Serum tuberculosis biomarkers and their association with clinical characteristics among hospitalized adults living with HIV in Uganda.Journal of clinical tuberculosis and other mycobacterial diseases · 2026Article
- Emerging insights into CC and CXC chemokines and their receptors in Mycobacterium tuberculosis infection.FEBS open bio · 2026Review
- Biodetection of Mycobacterium tuberculosis: nano-biosensors in detection; from principles to recent progresses.Journal of biological engineering · 2026Review
- Host-protein biomarkers distinguish asymptomatic TB in an active case finding study.IJTLD open · 2025Article
- Auxiliary Diagnostic Value of the Interferon Gamma-Induced Protein 10 mRNA Release Assay for Tuberculosis in People Living with HIV/AIDS - Beijing Municipality, China, 2022-2024.China CDC weekly · 2025Article
- The blood biomarker combination IL-8/IL-33 and IL-18/IL-33 distinguish between active tuberculosis and latent infection.Infection · 2025Article
- Article
- Previous COVID-19 infection significantly reduces elastase levels in newly diagnosed pulmonary tuberculosis patients.Frontiers in immunology · 2025Article
- A longitudinal prospective study of active tuberculosis in a Western Europe setting: insights and findings.Infection · 2024Article
- Review
- Challenges and the Way forward in Diagnosis and Treatment of Tuberculosis Infection.Tropical medicine and infectious disease · 2023Review
- Evaluation of theFrontiers in cellular and infection microbiology · 2023Article
- Evaluation ofFrontiers in cellular and infection microbiology · 2023Article
- Diagnostic Performance of a NovelFrontiers in microbiology · 2022Article
- Interferon-γ-Inducible Protein 10 (IP-10) Kinetics after Antiretroviral Treatment Initiation in Ethiopian Adults with HIV.Microbiology spectrum · 2021Article
- Microarray-based selection of a serum biomarker panel that can discriminate between latent and active pulmonary TB.Scientific reports · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundsPulmonary tuberculosis (PTB) is a major health and economic burden. Accurate PTB detection is an important step to eliminating TB globally. Interferon gamma-induced protein 10 (IP-10) has been reported as a potential diagnostic marker for PTB since 2007. In this study, a meta-analysis approach was used to assess diagnostic value of IP-10 for PTB.
methodsWeb of Science, PubMed, the Cochrane Library, and Embase databases were searched for studies published in English up to February 2019. The pooled sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic odds ratio (DOR), the area under the curve (AUC) and hierarchical summary receiver operating characteristic (HSROC) curve were estimated by the HSROC model and random effect model.
resultsEighteen studies including 2836 total participants met our inclusion criteria. The pooled sensitivity, specificity, PLR, and NLR of IP-10 for PTB detection were 86, 88%, 7.00, and 0.16, respectively. The pooled DOR was 43.01, indicating a very powerful discriminatory ability of IP-10. The AUC was 0.93 (95% CI: 0.91-0.95), showed the accuracy of IP-10 was good. Meta-regression showed that there was no heterogeneity with respect to TB burden, study design type, age, IP-10 assay method, IP-10 condition and HIV-infection status.
conclusionsOur results showed that IP-10 is a promising marker for differentiating PTB from non-TB.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.